Analyst Report from Bioshares
3 August 2018
David Blake and Mark Pachacz
At the 14th Bioshares Biotech Summit, the CEOs of four companies were each asked to address the topic, ‘The Investment Proposition – Does the Means Justify the End?’. The inspiration for this topic is that while the development and commercialisation of medical devices and diagnostics is not only capital intensive but lengthy, success is to be measured by product revenues. Bioshares summarises the presentations from Micro-X and LBT Innovations.